Hydroxyurea interferes with antigen-dependent T-cell activation in vitro

Eur J Clin Invest. 2000 Feb;30(2):162-6. doi: 10.1046/j.1365-2362.2000.00574.x.

Abstract

Background: Hydroxyurea is believed to inhibit human immunodeficiency virus type 1 (HIV-1) in HIV disease by decreasing the amount of intracellular deoxynucleotides needed for viral replication. A plasma concentration of 400 micromol L-1 is tolerated in oncological diseases. The present study focused on the possible interference of hydroxyurea with antigen-dependent T-cell activation as an alternative explanation for inhibiting HIV replication in vivo.

Methods: The effect of hydroxyurea on common antigen-induced cell proliferation was studied in peripheral blood mononuclear cells (PBMC) in vitro.

Results: Hydroxyurea inhibited Candida albicans-induced cell proliferation at a low concentration (1 micromol L-1), while at least 10 micromol L-1 was required to block HIV-1 replication in phytohaemagglutinin (PHA)-stimulated PBMC.

Conclusion: Hydroxyurea inhibits antigen-induced lymphoproliferation in vitro at a concentration at which it does not inhibit PHA-induced HIV replication. Hydroxyurea may inhibit HIV-1 in CD4+ T cells in vivo not only by decreasing the amount of intracellular deoxynucleotides, but more specifically by interfering with antigen-dependent T-cell activation, thereby causing a reduction in the number of HIV target cells.

Publication types

  • Comparative Study

MeSH terms

  • Candida albicans / immunology
  • HIV-1 / drug effects
  • Humans
  • Hydroxyurea / pharmacology*
  • Lamivudine / pharmacology
  • Lymphocyte Activation / drug effects*
  • Phytohemagglutinins / immunology
  • Reverse Transcriptase Inhibitors / pharmacology
  • T-Lymphocytes / drug effects*
  • T-Lymphocytes / virology
  • Zidovudine / pharmacology

Substances

  • Phytohemagglutinins
  • Reverse Transcriptase Inhibitors
  • Lamivudine
  • Zidovudine
  • Hydroxyurea